companies / insilico-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-05 json
| total_raised | 110,000,000110.0M | ○ |
|---|---|---|
| founded | null | |
| hq | Cambridge MA | |
| industry | unknown | |
| stage | series-b+ |
Insilico Medicine uses generative AI to design novel drug candidates, predict clinical trial outcomes, and accelerate hit-to-lead optimization for pharma partners and its own pipeline. Its end-to-end platform covers target discovery, molecular design, and synthesis planning, moving its lead fibrosis compound into Phase II trials.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-03-01 | series-d+ | 110,000,000110.0M | null | ○ |
Tilda, reCAPTCHA, PHP, DDoS-Guard, Hammer.js
| fact | status | src |
|---|---|---|
| Series D+, $110.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |